NRx Builds Momentum From FDA Progress To Strategic Expansion

Pharmaceutical company NRx makes progress on new drug applications and expands its network of mental health clinics.

Published on Feb. 27, 2026

Got story updates? Submit your updates here. ›

NRx Pharmaceuticals, a clinical-stage biopharmaceutical company, is making progress on its developmental drug NRX-100 for treating suicidal depression. The company had a successful meeting with the FDA and plans to file a New Drug Application. NRx is also expanding its HOPE Therapeutics subsidiary, which operates a network of mental health clinics offering treatments like ketamine, TMS, and hyperbaric oxygen therapy. Additionally, the company is advancing its NRX-101 drug for suicidal treatment-resistant bipolar depression and chronic pain.

Why it matters

NRx's progress on its drug candidates and the expansion of its mental health clinic network could provide new treatment options for the millions of Americans who struggle with suicidal depression, PTSD, and other mental health issues. The company's focus on developing safer, more effective alternatives to existing therapies like ketamine could be a significant advancement in this area.

The details

NRx completed an in-person meeting with the FDA over NRX-100, its developmental drug for treating suicidal depression. The company plans to file a New Drug Application for NRX-100 based on existing clinical trial data and real-world evidence. NRx also filed an Abbreviated New Drug Application for a preservative-free ketamine formulation, which it expects to receive FDA approval for in summer 2026. To expand its reach, NRx launched its HOPE Therapeutics subsidiary, which operates mental health clinics that combine neuroplastic drugs with other therapies like TMS and hyperbaric oxygen. NRx has also been acquiring additional clinics to grow this network. Separately, the company is advancing its NRX-101 drug, which is an FDA-designated Breakthrough Therapy for suicidal treatment-resistant bipolar depression and chronic pain.

  • NRx filed an Abbreviated New Drug Application for its preservative-free ketamine formulation in September 2025.
  • NRx expects a summer 2026 decision date from the FDA on its Abbreviated New Drug Application.

The players

NRx Pharmaceuticals, Inc.

A clinical-stage biopharmaceutical company developing therapeutics based on its NMDA platform for the treatment of central nervous system disorders, specifically suicidal bipolar depression, chronic pain and PTSD.

HOPE Therapeutics

A subsidiary of NRx Pharmaceuticals that operates a network of mental health clinics offering treatments like ketamine, TMS, and hyperbaric oxygen therapy.

neurocare group AG

A company that NRx recently teamed up with to provide a neuroplastic therapy that combines specialized medication with advanced brain stimulation techniques to treat mental health issues.

Dr. Jonathan Javitt

The founder, Chairman and CEO of NRx Pharmaceuticals.

Anson Funds LLC

A firm that NRx Pharmaceuticals had an outstanding debt with, which was swapped for common stock to eliminate the company's remaining $5.4 million in balance sheet debt.

Got photos? Submit your photos here. ›

What they’re saying

“We deeply appreciate the FDA's meeting with us at the leadership level and guiding us to pursue a New Drug Application for NRX-100 for the benefit of the millions of Americans who tragically form a plan to end their lives each year.”

— Dr. Jonathan Javitt, Founder, Chairman and CEO of NRx Pharmaceuticals

What’s next

The judge in the case will decide on Tuesday whether or not to allow Walker Reed Quinn out on bail.

The takeaway

NRx's progress on its drug candidates and the expansion of its mental health clinic network could provide new treatment options for the millions of Americans who struggle with suicidal depression, PTSD, and other mental health issues. The company's focus on developing safer, more effective alternatives to existing therapies like ketamine could be a significant advancement in this area.